Halozyme grants director RSUs and stock options

Halozyme director Dannielle Appelhans received RSU and stock option awards that vest at the 2027 annual stockholders’ meeting.

Rhea-AI Filing Summary

HALOZYME THERAPEUTICS, INC. (HALO) reported that director Dannielle Appelhans received equity-based compensation on September 1, 2026. She was granted 1,161 Restricted Stock Units, each representing one common share, and options to purchase 1,778 shares of common stock at an exercise price of $107.72 per share. Both the RSUs and the stock options are scheduled to vest in full on the date of Halozyme’s 2027 annual meeting of stockholders. No Rule 10b5-1 trading plan is reported for these awards.

Insider Trade Summary

Grant/Award: 2,939 shares

Grant/Award 2 txns

Insider Appelhans Dannielle

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Option to Purchase Common Stock F2	1,778	$0.00	$0.00
Grant/Award	Restricted Stock Units F1	1,161	$0.00	$0.00

Holdings After Transaction: Option to Purchase Common Stock — 1,778 contracts (Direct); Restricted Stock Units — 1,161 shares (Direct)

Footnotes (2)

1. F1. Represents restricted stock units granted under the Issuer's director compensation program. Each stock unit represents the right to receive one share of common stock and is scheduled to vest on the date of the Issuer's 2027 annual meeting of stockholders.
2. F2. Represents stock options granted under the Issuer's director compensation program. This grant will vest in full on the date of the Issuer's 2027 annual meeting of stockholders.

Key Figures

RSUs granted: 1,161 shares Options granted: 1,778 shares Option exercise price: $107.72 per share +3 more

6 metrics

RSUs granted 1,161 shares Restricted Stock Units granted to director Dannielle Appelhans on September 1, 2026

Options granted 1,778 shares Stock options granted to Dannielle Appelhans on September 1, 2026

Option exercise price $107.72 per share Exercise price for options to purchase 1,778 Halozyme common shares

RSU post-transaction holdings 1,161 RSUs Total RSUs directly held by Dannielle Appelhans after the transaction

Option post-transaction holdings 1,778 options Total options directly held by Dannielle Appelhans after the grant

Option expiration date September 1, 2036 Expiration date of the 1,778 stock options granted

Key Terms

Restricted Stock Units, stock options, director compensation program, exercise price

4 terms

Restricted Stock Units financial

"Represents restricted stock units granted under the Issuer's director compensation program."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

stock options financial

"Represents stock options granted under the Issuer's director compensation program."

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

director compensation program financial

"granted under the Issuer's director compensation program."

exercise price financial

"conversion or exercise price 107.7200"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Halozyme (HALO) director Dannielle Appelhans receive?

Dannielle Appelhans received 1,161 Restricted Stock Units and options to purchase 1,778 shares of Halozyme common stock on September 1, 2026, as part of the company’s director compensation program.

What is the exercise price of the new Halozyme (HALO) stock options?

The newly granted Halozyme stock options to director Dannielle Appelhans have an exercise price of $107.72 per share, with options covering 1,778 shares of common stock.

When do the new Halozyme (HALO) RSUs and options for Dannielle Appelhans vest?

Both the 1,161 RSUs and the 1,778 stock options granted to director Dannielle Appelhans are scheduled to vest in full on the date of Halozyme’s 2027 annual meeting of stockholders.

Are the Halozyme (HALO) equity grants to Dannielle Appelhans part of a director compensation program?

Yes. The filing states that both the Restricted Stock Units and the stock options were granted under Halozyme’s director compensation program.

Were the Halozyme (HALO) equity awards to Dannielle Appelhans made under a Rule 10b5-1 plan?

No. The filing indicates that the Rule 10b5-1 checkbox is not marked, so no Rule 10b5-1 trading plan is reported in connection with these equity grants.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 04:59 PM EDT Accepted by SEC EDGAR 09/02/2026 - 04:59 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Appelhans Dannielle

(Last) (First) (Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Restricted Stock Units	09/01/2026		A		1,161(1)	A	$0	1,161	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$107.72	09/01/2026		A		1,778		(2)	09/01/2036	Common Stock	1,778	$0	1,778	D

Explanation of Responses:

1. Represents restricted stock units granted under the Issuer's director compensation program. Each stock unit represents the right to receive one share of common stock and is scheduled to vest on the date of the Issuer's 2027 annual meeting of stockholders.

2. Represents stock options granted under the Issuer's director compensation program. This grant will vest in full on the date of the Issuer's 2027 annual meeting of stockholders.

Remarks:

	/s/ James R. Oehler, Attorney-in-Fact	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)